Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes sir. Stock has also held well since the lift off of 1cent due to 6 month data release of Adipocell. June (the month were in) is also the month for the final data collection for phase 1 for Adipocell. At 6 months data release we peaked at 8 cents, the possibilities with 12 month data are far greater IMO specially with a higher starting point such as the situation were in now.
Yeah all that is in the past... Where are we today?? Increased revenues. Strategic partnerships. Phase 3 Myocell. Closing phase 1 Adipocell. Etc
The past is irrelevant. The future looks bright.
Lol that have me a good laugh. However, the inevitable is becoming more apparent. If we don't hear from you after Monday... Best of luck demon.
What makes you say that?
I'm sorry but... That's not BioHeart as the one represented by the stock symbol BHRT that we discuss here.
http://ih.advfn.com/p.php?pid=nmona&article=62437299&xref=newsalert
That's a whole lot of shares.
"Generally speaking, both U.S. payers and retinal specialists appear ready to embrace future high-cost GA drugs, suggesting a smooth path to market entry and potentially strong uptake for the first agents approved for this highly underserved patient population."
http://www.marketwatch.com/story/surveyed-us-retinal-specialists-are-highly-receptive-to-pipeline-agents-targeting-geographic-atrophy-the-dry-form-of-advanced-age-related-macular-degeneration-2014-06-04
Hey I remember reading something to this extent and understanding, have to go back to verify but my understanding was that the reason for the increase in shares was to maintain majority share holders in case of a partnership. By having additional shares that BioHeart leadership team can issue to themselves... No partner can become a majority share holder and completely take over BioHeart. Do you remember reading this I believe in the DEF14C?
Excellent correlation. Excited for the future.
I see your perspective but I'm hoping for a JV... Makes sense to me that they intend to bring in a CEO with prestige, which is why they would not crown our interim CEO, CEO.
Does this mean we have a CEO coming?
Manuscript detailing interim data under review at impactful journal
Co-authored by participating surgeons and company
o Clean safety profile
o Evidence of engraftment and persistence of transplanted RPE cells
o Persisting Improvement of Visual Acuity for many patients A number of patients with clinically significant improvements in BCVA
AMD-207 improved 20/400 to 20/40
• Improvement has persisted through follow-up visits (> 1 year)
SMD-001 improved from HM to 20/500
• Improvement (with further gains) has persisted through follow-up visits (>2 year)
› Active dialog with MHRA and FDA
› Anticipate P2 commencement in 2H2014
Exemplars of Patients With
Improved Visual Acuity
Based on advice from all 5 clinical trial sites and participating surgeons, as well as input from regulators, we are advancing to phase 2 studies
http://content.stockpr.com/advancedcell/db/Presentations/3484/file/ACT+Corporate+Presentation+-+May+2014+-+PRINT+VERSION.pdf
Stay tuned for updates on our Chief Scientific Officer, Kristin Comella, attending the TOBI Conference next week!
http://www.prpseminar.com/5th-annual-prp-regenerative-medicine-symposium-june-6-7-2014-tobi-2014/
Thanks chuck, are you referring to the latest slides or is there some sort of overview/blog I can't seem to find... Forgive my ignorance. Can you provide me a link please?
Quick question, what do you mean by "and now the website"? Does look a bit different, a bit cleaner...
Excellent post chuck. The reason for the success with extremely low dosages is that we are the only company authorized to use the gold standard of stem cells... HESCs.
A researcher in the vanguard of stem-cell science
It’s been done with sheep, frogs, mice and even infant human cells, but no one had had success in cloning cells from adults, a much more challenging feat since decades of development have to be erased and reprogrammed. Dr. Robert Lanza, chief scientific officer at biotech firm Advanced Cell Technology, working with a group of researchers at CHA University in South Korea, changed all that.
His team inserted DNA from a donor cell into an egg stripped of its own genetic code, but the goal isn’t to create mini-mes. Instead, the method could mean a new way to make stem cells, which could then be turned into new nerve, muscle or insulin-producing cells to treat or even cure diseases like Alzheimer’s and diabetes.
The breakthrough is sweet for Lanza, who spent years defending work on stem cells extracted from excess IVF embryos at a time when lawmakers and the White House banned federal funding for some studies. The controversies may continue, but thanks to Lanza the science will too.
http://time.com/72173/robert-lanza-2014-time-100/
Guess not. Hopefully we hear some news from the world stem cell conference
It's all there in plain sight. 2H of 2014 is a little over a month from now and IMO phase 2 commencement means new highs.
Yeah I agree. If convertibles are not convertible beyond .03 then it makes sense to convert before major news hits and convertibles are no longer because of new highs that are out of reach.
Don't forget the most recent 10Q
Bioheart Reports Significant Revenue Increases
SUNRISE, FL--(Marketwired - May 15, 2014) - Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced today its financial results for the first quarter of 2014.
Product revenues during the first quarter of 2014 were $322,572, compared to $4,192 during the first quarter of 2013. In addition, this is a 98% increase over the fourth quarter revenue of $157,055. The revenues recognized to date are related to sales of MyoCath, patient treatments, AdipoCell system and related supplies, and cell culturing and banking services. Cost of sales consists of the costs associated with the production of MyoCath, laboratory supplies necessary for laboratory services, production of AdipoCell systems and materials, and clinic supplies required for patient studies. Cost of sales was $94,446 in the three-month period ended March 31, 2014, which is a gross margin of 71%.
"A solid team and business plan has led to this strong start to 2014," said Mike Tomas, President and Chief Executive Officer of Bioheart. "We have already made great progress and are poised for continued momentum."
Good perspective, no need for a panic. Hold on to shares and nothing is unchanged because the target price you intend to sell at will come soon, lots in the works for BioHeart.
But if you panic and sell the loss.... You lose. Remember, for the stock price to go down... Buys have to occur.
Does anyone know what is going on?
A lot has changed.... But here's the most recent reason, REVENUE.
Bioheart Reports Significant Revenue Increases
SUNRISE, FL--(Marketwired - May 15, 2014) - Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced today its financial results for the first quarter of 2014.
Product revenues during the first quarter of 2014 were $322,572, compared to $4,192 during the first quarter of 2013. In addition, this is a 98% increase over the fourth quarter revenue of $157,055. The revenues recognized to date are related to sales of MyoCath, patient treatments, AdipoCell system and related supplies, and cell culturing and banking services. Cost of sales consists of the costs associated with the production of MyoCath, laboratory supplies necessary for laboratory services, production of AdipoCell systems and materials, and clinic supplies required for patient studies. Cost of sales was $94,446 in the three-month period ended March 31, 2014, which is a gross margin of 71%.
"A solid team and business plan has led to this strong start to 2014," said Mike Tomas, President and Chief Executive Officer of Bioheart. "We have already made great progress and are poised for continued momentum."
I believe were in for an interesting week.
Did you see this one GS?
http://www.digitaljournal.com/pr/1917294
Awesome news this morning. As investaholic mentioned, the World Stem Cells Regenerative Medicine Congress is a huge event!
No MMs today?
Yeah I'll be adding next week as well.
It will be soon!
The stock is up 170% YTD... How do you figure it is down??